The role of ifosfamide in the treatment of lymphomas

Leukemia and Lymphoma

Volumn 34, Issue 5-6, 1999, Pages 433-441

  Hagemeister, Fredrick B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ifosfamide; Non Hodgkin's lymphoma; Review; Therapy

Indexed keywords

ALKYLATING AGENT; AMSACRINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; MITOGUAZONE; MITOXANTRONE; PLATINUM; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

BLADDER DISEASE; BONE MARROW RESCUE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLASSIFICATION; CLINICAL TRIAL; HUMAN; LYMPHOMA; META ANALYSIS; NEUROTOXICITY; OUTPATIENT; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RELAPSE; REVIEW; SCREENING; STEM CELL TRANSPLANTATION; TUMOR RESISTANCE;

EID: 0032857773     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909058470     Document Type: Review

References (60)

1. Martelli M, De Sanctis V, Avvisati G, Mandelli F. (1997) Current guidelines for the management of non-Hodgkin's lymphoma. Drugs, 53, 957-972.
2. Reis LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK (eds). (1998) SEER Cancer Statistics Review, 1973-1995. Bethesda, MD: National Cancer Institute.
3. American Cancer Society. (1998) Cancer Facts & Figures-1998. Atlanta: American Cancer Society.
4. Bosly A, Coiffier B. (1997) Recent data on the epidemiology of non-Hodgkin's lymphomas. Groupe dEtudes des Lymphomes de l'Adulte (GELA). Pathologie Biologie, 45, 449-452.
5. The Non-Hodgkin's Lymphoma Pathologic Classification Project. (1982) National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation of clinical usage. Cancer, 49, 2112-2135.
6. Harris NL, Jaffe ES, Stein H. Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
7. Hiddemann W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, Nadler LM, De Vita VT, Lister A, Armitage JO. (1996) Lymphoma classification: the gap between biology and clinical management is closing. Blood, 88:4085-408.
8. Melnyk A, Rodriguez A, Pugh WC, Cabanillas F. (1997) Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood, 89,4514-4520.
9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
10. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. (1994) Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. Journal of Clinical Oncology, 12, 1343-1348.
11. Wiernik P. Ozer H, Oken M, Giles F, Solal-Celigny P, Coiffier B. (1997) Prognostic factors in patient selection for treatment with interferon alfa in low-grade follicular lymphoma. Blood, 90 (Suppl 1). 337a.
12. Hoppe RT. (1985) The role of radiation therapy in the management of the non-Hodgkin's lymphomas. Cancer, 55, 2176-2183.
13. Connors JM, Klimo P, Fairey RN, Voss N. (1987) Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Annals of Internal Medicine, 107, 25-30.
14. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 339, 21-26.
15. Goldie JH, Coldman AJ, Gudauskas GA. (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treatment Reports, 66, 439-449.
16. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C Jr, Moon TE. (1976) Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, 1484-1493.
17. Canellos GP, Skarin AT, Klatt MM, Rosenthal D, Case DC Jr, Pinkus GS, Jochelson MS, Yeap BY, Shipp MA. (1987) The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Seminars in Hematology, 24(2 Suppl 1), 2-7.
18. Fisher RI, DeVita VT Jr, Hubbard SM, Longo DL, Wesley R, Chabner BA. (1983) Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of Pro-MACE and MOPP chemotherapy. Annals of Internal Medicine, 98,304-309.
19. Klimo P. Connors JM. (1985) MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Annals of Internal Medicine, 102,596-602.
20. Fisher RI, Gaynor ER, Dahlberg S Oken MM, Grogan TM, Mize EM. Glick JH, Coltman CA Jr, Miller TP. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
21. Goss PE. (1992) New perspectives in the treatment of non-Hodgkin's lymphoma. Seminars in Oncology, 19 (6 Suppl 12), 23-30.
22. Nowrousian MR, Burkert H, Herdrich K, Pohl J. (1993) Ifosfamide in Cancer Therapy - A Comparison with Cyclophosphamide. Frankfurt, ASTA Medica AG. pp 1-123.
23. Allen LM, Creaven PJ. (1973) Interaction of mechlorethamine and isophosphamide with bovine serum albumin and rat liver microsomes. Journal of Pharmaceutical Science, 62, 854-856.
24. Goren MP. (1996) Oral administration of mesna with ifosfamide. Seminars in Oncology, 23 (3 Suppl 6), 91-96.
25. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. (1996) Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Seminars in Oncology, 23(3 Suppl 6), 97-98.
26. Morgan LR, Harrison EF. Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG, Worrall PM. (1982) Toxicity of single vs fractionated-dose ifosfamide in non-small cell lung cancer: a multicenter study. Seminars in Oncology. 9 (4 Suppl 1), 66-70.
27. Case DC Jr, Anderson J, Ervin TJ, Gottlieb A. (1988) Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552. Medical and Pediatric Oncology, 16, 182-186.
28. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology, 5, 407-412.
29. Goss PE. (1993) Non-Hodgkin's lymphomas in elderly patients. Leukemia and Lymphoma, 10, 147-56.
30. Nowrousian MR, Meier CR, Schoetensack B, Anders C, Hoffken K, Osieka R, Schmidt CG. (1989) Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma. Acta Oncologica, 28, :495-500.
31. Dumont J, Charpy-Validire P, Mosseri V, Gabarre J, Belanger C, Turpin F, Binet JL, Dreyfus F, Fourguet A, Janvier M, LeDoussal M, Missenard V, Natali JC, Raphael M, Teillet F, Teillet-Thiebaud F, Tulliez M, Varet B, Vilcoq JR, Asselain B. (1991) Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma. Hematological Oncology, 9, 197-207.
32. Koppler H, Pfluger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Steinhauer EU, Gropp C, Oehl S, Lotzke E, Kuhn H, Drings P, Gossmann H, Lennert K, Stein H, Havemann K. (1991) Sequential versus alternating chemotherapy for high grade non-Hodgkin's lymphomas: a randomized multicentre trial. Hematological Oncology, 9, 217-23.
33. Steinke B, Bross K, Reinold HM, Heim ME, Schalk KP, Heidemann E, Josten K, Arnold H, Manegold C, Hoffman I, Zwingers T, Feller AC, Muller-Hermelink HK. (1992). Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP. European Journal of Cancer, 28, 100-104.
34. De Lena M, Ditonno P, Lorusso V, Brandi M, Timurian A, Marzullo F, Ventrella V, Pellecchia A. (1995) CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study. Journal of Clinical Oncology, 13, 953-60.
35. Cabanillas F. (1990) Ifosfamide combinations in lymphoma. Seminars in Oncology, 17(2 Suppl 4), 58-62.
36. Armitage JO. (1993) Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023-1030.
37. Armitage JO, Vose JM, Bierman PJ, Bishop MR. (1994) Salvage therapy for patients with lymphoma. Seminars in Oncology, 21(4 Suppl 7), 82-85.
38. Rodriguez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ. (1978) Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treatment Reports, 62, 493-497.
39. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. (1982) IMVP-16, an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood, 60, 693-697.
40. Nowrousian MR, Anders CH. Niederle N, Nagel-Hiemke M. Moritz T. Seeber S, Schmidt CG. (1991) Etoposide, ifosfamide, methotrexate with or without bleomycin in refractory or recurrent lymphomas. Annals of Oncology, 2, 25-30.
41. Haim N, Rosenblatt E, Wollner M, Ben-Shahar M, Epelbaum R, Robinson E. (1992) Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin. Cancer Chemotherapy and Pharmacology, 30, 243-244.
42. Hickish T, Roldan A, Cunningham D, Mansi J, Ashley S, Nicolson V, Gore ME, Catovsky D, Smith IE. (1993) EPIC: an effective low toxicity regimen for relapsing lymphoma. British Journal of Cancer, 68, 599-604.
43. Richardson DS, Tighe M, Cull G. Johnson SA, Phillips MJ. (1984) Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule-EPIC. Hematological Oncology, 12, 125-128.
44. Okamoto M, Hirano M, Hotta T, Shirakawa S, Ohno R, Saito H. (1994) Dexamethasone, etoposide, ifosfamide and carboplatin (DeVIC): an effective salvage treatment for intermediate or high grade non-Hodgkin's lymphoma. Procedings of the American Society of Clinical Oncology, 13, 376(abstract 1272).
45. Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, Bendandi M, Ammendolia I, Salvucci M, Babini L, Tura S. (1994) Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica 79, 508-512.
46. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology, 13, 1734-1741.
47. Cabanillas F. (1992) Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience. Seminars in Oncology, 19(1 Suppl 1), 11-13.
48. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B. (1988). Effective salvage theapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117-122.
49. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. (1994) ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of Clinical Oncology. 12, 1169-1176.
50. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J-Y, Harousseau J-L, Coffier B, Biron P, Mandelli F, Chauvin F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkins lymphoma. New England Journal of Medicine, 333, 1540-1545.
51. Henon PR, Liang H, Beck-Wirth G. Eisenmann JC. Lepers M, Wunder E. Kandel G. (1992) Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplantation, 9, 285-291.
52. Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D. (1996) Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. Journal of Clinical Oncology, 14, 586-592.
53. Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R. (1997) Blood progenitor cell (BPC) mobilization in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Bone Marrow Transplantation, 19, 529-537.
54. Stamatoullas A, Fruchart C, Bastit D, Boulet D, Monconduit M, Piguet H, Tilly H. (1996) Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggresive non-Hodgkin's lymphoma. Cancer 77, 2302-2307.
55. Stamatoullas A, Fruchart C, Khalfallah S; Buchonnet G, Contentin N, Bastit D, Tilly H. (1996) Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplantation, 19, 31-35.
56. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE. Zorsky PE. (1995) Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Journal of Clinical Oncology, 13, 323-332.
57. Vose JM. (1996) Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Seminars in Oncology, 23(3 Suppl 6), 33-37.
58. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottier-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE. (1992) Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. Journal of Clinical Oncology, 10,1712-1722.
59. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, Gonin R, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. (1995) Phase I study of high-dose ifosfamide, carboplatin, and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplantation. 15, 373-379.
60. Kleiner S, Kirsch A, Schwaner I. Kingreen D, Schwella N. Huhn D. Siegert W. (1997) High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone Marrow Transplantation, 20, 953-959.